ELDERLY PATIENTS >65YEARS OF AGE WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME GAIN LIFE TIME FROM TREATMENT WITH TUMOR TREATING FIELDS AND TEMOZOLOMIDE

被引：0
|
作者：
Guzauskas, G. F. [1 ]
Wang, B. C. M. [1 ]
Kinzel, A. [2 ]
Proescholdt, C. [3 ]
机构：
[1] Univ Washington, Dept Pharm, Seattle, WA 98195 USA
[2] Novocure, Munich, Germany
[3] Novocure, Root, Switzerland
来源：
NEURO-ONCOLOGY | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P01.110
引用
收藏
页码：256 / 257
页数：2
相关论文
共 50 条
  • [31] Elderly patients aged 65–75 years with glioblastoma multiforme may benefit from long course radiation therapy with temozolomide
    C. Gzell
    H. Wheeler
    L. Guo
    M. Kastelan
    M. Back
    Journal of Neuro-Oncology, 2014, 119 : 187 - 196
  • [32] TUMOR TREATING FIELDS (TTFIELDS) COMBINED WITH LOMUSTINE (CCNU) AND TEMOZOLOMIDE (TMZ) IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS - A BI-CENTRIC ANALYSIS
    Lazaridis, L.
    Schaefer, N.
    Schmidt, T.
    Stoppek, A.
    Weller, J.
    Tzaridis, T.
    Scheffler, B.
    Pierscianek, D.
    Kleinschnitz, C.
    Stuschke, M.
    Sure, U.
    Herrlinger, U.
    Kebir, S.
    Glas, M.
    NEURO-ONCOLOGY, 2019, 21 : 81 - 81
  • [33] THE COST EFFECTIVENESS OF TUMOR TREATING FIELDS TREATMENT FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA BASED ON THE EF-14 TRIAL
    Guzauskas, Gregory
    Wang, Bruce C. M.
    Pollom, Erqi
    Stieber, Volker W.
    Garrison, Lou
    NEURO-ONCOLOGY, 2018, 20 : 116 - 116
  • [34] CHEMORADIATION (CRT) TREATMENT WITH OR WITHOUT CONCURRENT TUMOR-TREATING FIELDS (TTFIELDS) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Cappelli, Louis
    Kayne, Allison
    Pan, Peter
    Cordova, James
    Huang, Jiayi
    Wang, Tony
    Alnahhas, Iyad
    Shi, Wenyin
    NEURO-ONCOLOGY, 2022, 24 : 53 - 53
  • [35] Elderly patients aged 65-75 years with glioblastoma multiforme may benefit from long course radiation therapy with temozolomide
    Gzell, C.
    Wheeler, H.
    Guo, L.
    Kastelan, M.
    Back, M.
    JOURNAL OF NEURO-ONCOLOGY, 2014, 119 (01) : 187 - 196
  • [36] RANDOMIZED PHASE II TRIAL OF TUMOR TREATING FIELDS PLUS RADIATION THERAPY PLUS TEMOZOLOMIDE COMPARED TO RADIATION THERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Limon, D.
    Bokstein, F.
    Blumenthal, D.
    Ben Harush, C.
    Ram, Z.
    Grossman, R.
    NEURO-ONCOLOGY, 2019, 21 : 86 - 86
  • [37] TREATMENT DECISION AND QUALITY OF LIFE OF PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA RECEIVING TUMOR TREATING FIELDS (TTFIELDS) THERAPY IN ROUTINE CLINICAL CARE: RESULTS FROM THE TIGER STUDY
    Baehr, Oliver
    Tabatabai, Ghazaleh
    Fietkau, Rainer
    Goldbrunner, Roland
    Glas, Martin
    NEURO-ONCOLOGY, 2023, 25
  • [38] Chemoradiation treatment with or without concurrent tumor-treating fields (TTFields) therapy in newly diagnosed glioblastoma (GBM) patients in China
    Liping Liang
    Lingchao Chen
    Chunxia Ni
    Wenyin Shi
    Zhirui Zhou
    Shu Chen
    Wenjia Zhu
    Jiabing Liu
    Xianxin Qiu
    Wanzun Lin
    Junyan Zhang
    Zhiyong Qin
    Yang Wang
    Chinese Neurosurgical Journal, 11 (1)
  • [39] Tumor-Treating Fields Combined with Radiotherapy and Temzolomide for the Treatment of Newly Diagnosed Glioblastoma: Final Results from a Pilot Study
    Grossman, R.
    Bokstein, F.
    Ben Harosh, C.
    Ram, Z.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E99 - E99
  • [40] Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma A Secondary Analysis of a Randomized Clinical Trial
    Taphoorn, Martin J. B.
    Dirven, Linda
    Kanner, Andrew A.
    Lavy-Shahaf, Gitit
    Weinberg, Uri
    Taillibert, Sophie
    Toms, Steven A.
    Honnorat, Jerome
    Chen, Thomas C.
    Sroubek, Jan
    David, Carlos
    Idbaih, Ahmed
    Easaw, Jacob C.
    Kim, Chae-Yong
    Bruna, Jordi
    Hottinger, Andreas F.
    Kew, Yvonne
    Roth, Patrick
    Desai, Rajiv
    Villano, John L.
    Kirson, Eilon D.
    Ram, Zvi
    Stupp, Roger
    JAMA ONCOLOGY, 2018, 4 (04) : 495 - 504
12345